CAR-Team at Cellogen Therapeutics has conceptualized 10 state of art 3rd and 4th generation bi and tri specific CAR construct for b cell malignancies which the team has patented. These construct have been designed keeping in mind the pitfalls of existing constructs used across the globe and try to address them.